Hanall Biopharma Co., Ltd.

₩35,700As of Sun 8 Nov 2026, 12:00 UTC
KRX:009420Healthcare
Country South Korea
PE (Fwd) •••
TSR 10Y CAGR 11.68%
Div yield —
ROE (15.68%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.96
PE TTM —
TSR TTM (13.77%)
Mkt cap ₩1.816T
ROIC 2.26%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩36,411
1.99%
(47.65%)
Sell 2|4|11|4|5
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
347.99
358.38
359.00
361.94
5.05%
8.28%
11.64%
14.55%
Revenue₩B
100.3
99.30
103.0
102.4
8.47%
8.63%
6.98%
1.29%
Peers (US$1.339B)
Cap (US$)
PE
1.179B
—
612.0M
10.54x
Capital
TTM
5Y
10Y
Leveragex
1.986
0.240
0.229
EBIT/Intx
14.37
0.851
0.661
Own earn%
46.99
117.99
114.45
Sh yield%
25.61
37.73
35.78
Owners
Insiders/Inst%
8.05
73.57
Short interest%
2.33
SBC / revenue%
2.83
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
13–17
$1 testx
0.8
Incr. ROIC%
6